Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK890.00. The company’s shares closed yesterday at DKK582.54.

Bullish option flow detected in Novo Nordisk (NVO) with 21,940 calls trading, 1.5x expected, and implied vol increasing almost 3 points to 37.88%. Feb-25 85 calls and Feb-25 83 calls are the most ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing deal worth up to $1.3 billion. AstraZeneca is buying out its roxadustat ...

The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk’s NOVO.B5.83%increase; green up pointing triangle weight-loss medications Wegovy and Ozempic has been resolved ...

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage.

Novo Nordisk is seeking up to US$830 million (S$1.1 billion) in damages from KBP Biosciences, according to a ruling by a Singapore court, as the Danish drugmaker says it was misled when it bought ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. Adding 5m GLP-1 patients at slightly lower prices or 21m at LLY price levels both lead ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other oversold healthcare stocks to buy now. Healthcare costs and spending have been rising in ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...